Home › NDC Lookup › RxCUI directory › RxCUI 835726

Acamprosate calcium 333 MG Delayed Release Oral Tablet — RxCUI 835726

RxNorm drug concept · Semantic clinical drug
RxCUI 835726 Semantic clinical drug · SCD ● Current RxNorm concept 9 FDA products 20 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI835726
Official nameAcamprosate calcium 333 MG Delayed Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asacamprosate calcium 333 MG (acamprosate 300 MG) Delayed Release Oral Tablet
FDA products mapped9
Package NDCs mapped20
Reported Medicaid activity (SDUD)89,900 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Acamprosate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • No, acamprosate doesn't cause any kind of reaction if you drink alcohol. It won't make you feel sick or flushed the way disulfiram (Antabuse) does. What it's designed to do is help...
  • What exactly does acamprosate do — does it make me sick if I drink?
  • Yes — and this is really important. Acamprosate is only effective if you've already gone through alcohol withdrawal and are alcohol-free when you start. It hasn't been shown to hel...
  • Do I have to be completely sober before I start taking this?
📖 Read our full Acamprosate guide →

🕸️ Concept Web — How Acamprosate calcium 333 MG Delayed Release Oral... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Acamprosate calcium 333 MG Delayed Release Oral Tablet RxCUI 835726

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Acamprosate 82819
    • Acamprosate calcium 152761
  2. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Acamprosate Delayed Release Oral Tablet 802194
    • Acamprosate calcium Delayed Release Oral Tablet 2646837
    • Acamprosate Oral Product 1163659
    • Acamprosate Pill 1163660
    • Acamprosate calcium Oral Product 2660012
    • Acamprosate calcium Pill 2662209
    • Delayed Release Oral Tablet 10312
    • Oral Product 1151131
    • +1 more in this family
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Acamprosate calcium 333 MG 835725

Showing up to 8 concepts per family — 11 of 12 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Acamprosate calcium 333 MG SCDC · 835725
  • Acamprosate Delayed Release Oral Tablet SCDF · 802194
  • Acamprosate calcium Delayed Release Oral Tablet SCDFP · 2646837
  • Acamprosate Oral Product SCDG · 1163659
  • Acamprosate Pill SCDG · 1163660
  • Acamprosate calcium Oral Product SCDGP · 2660012
  • Acamprosate calcium Pill SCDGP · 2662209

📦 FDA Products & Package NDCs

9 products · 20 package NDCs
20 package NDCs map to RxCUI 835726 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00378-6333-80 180 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (0378-6333-... Acamprosate Calcium Mylan Pharmaceuticals Inc. 2014-09-24
00615-8560-39 30 TABLET, DELAYED RELEASE in 1 BLISTER PACK (0615-8560-39) Acamprosate Calcium NCS HealthCare of KY, LLC dba Vangard Labs 2025-02-18
00904-7213-04 30 BLISTER PACK in 1 CARTON (0904-7213-04) / 1 TABLET, DELA... Acamprosate Calcium Major Pharmaceuticals 2013-07-16
60687-0121-25 30 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-121-25) / 1 TABL... Acamprosate Calcium American Health Packaging 2015-10-27
68382-0569-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-01) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68382-0569-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-05) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68382-0569-06 30 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-06) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68382-0569-10 1000 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-10) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68382-0569-16 90 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-16) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68382-0569-28 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68382-569-28) acamprosate calcium Zydus Pharmaceuticals (USA) Inc. 2017-06-01
68462-0435-11 10 BLISTER PACK in 1 CARTON (68462-435-11) / 10 TABLET, DEL... Acamprosate Calcium Glenmark Pharmaceuticals Inc., USA 2013-07-16
68462-0435-18 180 TABLET, DELAYED RELEASE in 1 BOTTLE (68462-435-18) Acamprosate Calcium Glenmark Pharmaceuticals Inc., USA 2013-07-16
69452-0353-25 180 TABLET, DELAYED RELEASE in 1 BOTTLE (69452-353-25) Acamprosate Calcium Bionpharma Inc., 2025-12-01
70518-4616-00 50 POUCH in 1 BOX (70518-4616-0) / 1 TABLET, DELAYED RELEAS... acamprosate calcium REMEDYREPACK INC. 2026-04-23
70771-1057-00 1000 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-0) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
70771-1057-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-1) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
70771-1057-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-3) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
70771-1057-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-5) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
70771-1057-08 180 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-8) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
70771-1057-09 90 TABLET, DELAYED RELEASE in 1 BOTTLE (70771-1057-9) acamprosate calcium Zydus Lifesciences Limited 2017-06-01
Observed labelers: Zydus Lifesciences Limited (6) · Zydus Pharmaceuticals (USA) Inc. (6) · Glenmark Pharmaceuticals Inc., USA (2) · American Health Packaging (1) · Bionpharma Inc., (1) · Major Pharmaceuticals (1) · +3 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.6077
Range $0.6077–$0.6077 · middle 50% $0.6077–$0.6077 · 6 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.